Newsroom
-
January 16 , 2020
Chinese Immuno-Oncology Firm I-Mab's IPO Lands on NASDAQ
- I-Mab is the first Chinese company in two years to try the US boards for an IPO.
Read more -
January 10 , 2020
Biotech Stocks Facing FDA Decision In January 2020
- As we begin the first month of the year 2020, it’s time to take a look at the drug candidates lined up at the FDA altar awaiting the federal agency's decision.
Read more -
January 1 , 2020
First China-made HPV vaccine approved
- BEIJING, Jan. 2 (Xinhua) -- China has approved the first domestically produced vaccine against the cancerogenic human papillomavirus (HPV), according to the National Medical Products Administration (NMPA).
Read more -
December 20 , 2019
Tracon Pharma Acquires US Rights to 3D Medicines/Alphamab PD-L1
- SAN DIEGO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc.(NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, announced today that it has signed a collaborative partnership agreement with 3D Medicines (Beijing) Co., Ltd., a China-based biopharmace
Read more -
December 12 , 2019
GEN：Top 10 Immuno-Oncology Startups of 2019
- Alex Trebek appeared well en route to surviving pancreatic cancer this past summer when his doctors followed up his initial successful chemotherapy with an undisclosed immunotherapy. That move backfired.
Read more -
December 6 , 2019
8 Biopharma Trends to Watch in 2020
- According to the article “8 Biopharma Trends to Watch in 2020” published by Alex Philippidis on GEN（Genetic Engineering & Biotechnology News）, there are eight biopharma-related trends in the coming new year. Presidential election, mergers and acquisitions, gene therapy CDMOs, Alzheimer’s disease, venture capital deals, CRISPR legal wrangle, genome editing ad
Read more -
December 1 , 2019
2019 report advancing health through innovation
- Happy New Year! The beginning of a new year is always a rewarding time for the many dedicated staff at the FDA's Center for Drug Evaluation and Research (CDER) who work on approving new drug therapies. We look back over the past year and see how the work we did came together to help patients in need — one of the main reasons why many of us, including me, hav
Read more -
June 13 , 2019
Following CAR-T pioneer¬s' footsteps, Tessa launches China JV in $120M deal
- These days just about every biotech serious about global development — and not just commercialization — has a Chi-na strategy. Tessa Therapeutics, a Baylor associated outfit based out of Singapore, is no exception.
Read more -
January 28 , 2019
Zai Lab nabs speedy China regulatory review for PARP drug Zejula
- Chinese regulatory officials are signaling that they’re ready to whisk Zejula through the regulatory process.
Read more -
January 3 , 2019
2019 M&A starts with a bang as BMS and Celgene agree $74bn merger
- The pairing will create a company with annual sales north of $34 billion, behind Pfizer, Novartis and Roche in terms of 2017 prescription drug sales and ahead of Merck & Co and Johnson & Johnson. There’s also plenty of scope for cost-cutting – the two companies think they can find $2.5 billion in “synergies” by 2022.
Read more -
October 1 , 2018
Three Emerging Positive Trends to Watch in China Opening Up Huge Long-term Market Opportunity
- Three positive developments in China have evolved recently that could benefit the development, regulatory, reimbursement and - perhaps just as importantly-investment framework for biopharma. While still early, the Chinese govt is shifting from a network mostly "closed" to US Biopharma towards a more "open" and pro-innovation stance for medicine that could th
Read more